Shares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41.6%, according to data from S&P Global Market Intelligence. By the time the market closed on Friday, the stock was still up 34.8%.

The catalyst that vaulted the gene editing specialist higher was the company's quarterly report, which included a surprise announcement.

On Wednesday, Editas Medicine released its fourth-quarter results, which were better than investors had hoped. The company generated revenue of $60 million and a loss per share of $0.23. Financial results generally take a back seat to other announcements with small drug developers, but these were notable, as analysts' consensus estimates were calling for revenue of $7.94 million and a loss per share of $0.54, so Editas sailed past expectations.

Continue reading

Source Fool.com